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Abstract
Cancer cells bypass replicative senescence, the major barrier to tumor progression, by using telomerase or alternative
lengthening of telomeres (ALT) as telomere maintenance mechanisms (TMMs). Correlation between ALT and patient
survival was demonstrated for high-grade astrocytomas. Transcription from subtelomeres produces telomeric repeat-
containing RNA (TERRA), a natural inhibitor of telomerase activity (TA). This led us to evaluate correlations of TERRA and
TMM with tumor grade and outcome in astrocytoma patients. SYBR Green real-time reverse transcription–polymerase
chain reaction assays for quantitation of total and chromosome 2p and 18p specific TERRA levels were developed.
Tumor samples from 46 patients with astrocytoma grade 2 to 4, tissue controls, and cell lines were assessed. TMMs
were evaluated by measuring TA and by detecting long telomeres due to ALT. In glioblastoma multiforme (GBM)
grade 4, total TERRA levels were similar to cell lines but 14-, 31-, and 313-fold lower compared with grade 3, grade 2,
and nonmalignant tissue, respectively. Total TERRA levels differed from chromosomal levels. Low 2p TERRA levels
correlated with dense promoter methylation of subtelomeric CpG islands, indicating that TERRA expression in gliomas
may be chromosome specific and epigenetically regulated. Total TERRA levels correlated with diagnosis, with low or
absent TA and the presence of ALT, and were tentatively associated with favorable patient prognosis in our cohort
(P= .06). TA and short telomeres identified a subset of GBMwith a median survival of only 14.8 months. TERRA and
TA may be prognostic in astrocytic tumors.
Translational Oncology (2012) 5, 56–65
Introduction
Telomeres are the ends of linear chromosomes that serve as a protec-
tive cap to avoid permanent proliferation arrest, termed replicative
senescence. In vertebrates, telomeres consist of tandem repeats of
TTAGGG hexanucleotide sequences and some repeats are lost in
each cell division [1]. The activation of a telomere maintenance
mechanism (TMM) results in immortalization and has been identi-
fied as a crucial hallmark of cancer cells [2,3].
Tumors use two TMMs, one based on telomerase activity (TA) and
the second, which does not use telomerase, named alternative length-
ening of telomeres (ALT) [4]. TA is the predominant mechanism
used by roughly 85% of human cancer [5], and its role in cancer
has been the focus of many reviews [6,7]. ALT is less commonly used,
but it has shown high prevalence in sarcomas and astrocytomas [8,9].
A characteristic finding of ALT in affected tumor cells is that the
mean telomere length (TL) analyzed by terminal restriction fragment
(TRF) Southern blots is substantially longer—approximately twice as
long as in normal cells—indicating that the telomeres had undergone
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extensive lengthening [10]. TA-positive cells regulate TLs around a
mean of 5 to 10 kb with normal distribution, whereas in ALT cells,
the telomeres are very large—up to 20 kb with considerable hetero-
geneity in length.
The first report demonstrating telomerase as a prognostic marker in
human malignancies was published on childhood neuroblastoma [11].
The question of whether telomerase and telomere dysfunction are
useful prognostic markers is still debated [12,13]. Glioblastoma multi-
forme (GBM, grade 4 astrocytoma) has a poor prognosis, with a median
survival less than 2 years despite multimodality therapy [14].
TA was reported in 78% (60/77 cases) of GBM but was less com-
monly observed in astrocytoma grade 3 tumors, with 28% (5/18 cases)
evidencing activity, and absent in astrocytoma grade 2 tumors (0/
10 cases) [15]. Similar correlations between TA and histologic grade
were published by other authors as well [16]. Although additional stud-
ies reported that 30% to 50% of GBM express TA [17,18]. However,
TA studied in a larger GBM cohort did not correlate with survival of
patients [19]. Previous studies reported the presence of ALT in a high
percentage of astrocytoma grades 2 and 3 and a positive association
between ALT and survival in GBM patients [8,19,20]. ALT detected
by TL has some limitations because this pattern is not identified in all
cells using ALT, and long telomeres are seen in cells using TA when
telomerase genes hTERT and hTR are expressed at supraphysiological
levels. Comparing different methods detecting ALT, the long hetero-
geneous TL pattern remains the best-established marker for ALT in
human cells, including tumors [9].
Recently, a class of noncoding telomeric repeat-containing RNA
(TERRA or TelRNA) transcripts has been reported as key components
of telomeres [21,22]. TERRA transcription by RNA polymerase II
originates in the subtelomeres of chromosome ends, and its expres-
sion depends on the epigenetic state of CpG island promoters [23].
Considering all chromosomal ends, more than 20 TERRA transcripts
are predicted by in silico analyses and are defined as telomeric transcrip-
tome [24]. Reduced TERRA expression and epigenetic regulation with
an increase in DNA methylation at the proximal subtelomere were
found associated with TA in a study of normal human fibroblasts
and cancer cell lines suggesting that TERRA may inhibit telomerase
[25]. Preliminary data of TERRA expression demonstrated down-
regulation in advanced stages of human tumors of larynx, colon, and
lymph node compared with normal tissues [22]. The results are con-
sistent with the notion that TERRA may inhibit telomerase because
these tumors are using frequently TA as TMM.
In this study, we analyzed TERRA expression and subtelomeric
methylation in a panel of astrocytoma grades 2 to 4 tumors and cell
lines and compared the results with TMM status and clinical vari-
ables. We hypothesized that TERRA expression would correlate with
prolonged survival in patients with astrocytomas. Total TERRA ex-
pression was determined after reverse transcription by a SYBR Green
real-time polymerase chain reaction (PCR) method published for
measuring relative telomeric repeat DNA content [26,27] and compared
with TERRA levels from subtelomeric regions of chromosomes 2p
and 18p. Methylation levels at the subtelomere of chromosome 2p
were determined by bisulfite allelic sequencing and correlated with
2p TERRA expression. TERRA transcript levels were compared with
nonmalignant brain tissue and decreased by tumor grade and correlated
with ALT and TA, as studied by TL and the telomeric repeat ampli-
fication protocol (TRAP) assay, respectively. TA was not detected in
astrocytoma grades 2 and 3 but in 50% of GBM. However, in grades 2
and 3 tumors, the mean TL measured by TRF analyses and PCR was
increased more than 17 kb, indicating a strong prevalence for ALT and
better outcome in these tumors as reported [19]. Indeed, elevated
TERRA levels, long telomeres, and absence of TA correlated with
low-grade and survival. In conclusion, we found that TERRA expres-
sion and TA correlated with outcome of this patient series, suggesting
that the correlation of TERRA and TA as prognostic markers in astro-
cytomas should be further investigated.
Materials and Methods
Patient Material and Cell Lines
Tissue samples were resected surgically from 46 patients with astro-
cytoma at the Department of Neurosurgery of the General Hospital
Vienna, Austria, between 2000 and 2007. The local research ethics
committee approved the study. Follow-up information was collected
until December 2008 and was available for 42 of 46 patients. Patients’
age at diagnosis and at last follow-up and survival were calculated from
the date of their first operation at which World Health Organization
grades 2 to 4 astrocytoma was confirmed histologically. Tissue sam-
ples from brain regions (hippocampus, cortex, and temporal mark)
were included from two patients experiencing drug-refractory epilepsy
as nontumor (NT) controls. The samples were snap frozen in liquid
nitrogen after surgical removal and stored at −80°C or in liquid nitrogen
until use. A synopsis of tumor tissue material and its relation to patient
data is given in Table 1.
Cell lines originating from astrocytoma CRL-1718 (CCF-STTG1),
CRL-2020 (DBTRG/05MG), CRL-1690 (T98G),HTB17 (U-373MG),
and HTB138 (Hs683) were obtained from the American Type Culture
Collection (ATCC, Manassas, VA) and were grown under standard con-
ditions. LN-140 cell line (kindly provided by Dr Tribolet, Lausanne,
Switzerland) and MR-1 and MGC glioblastoma cells (a gift from
Dr T. Kurata, Tokyo, Japan) were grown in minimal essential medium–
Eagle with 10% fetal calf serum. KG-MH, KM-YH, YT-BO, and
YU-PM were established from patient material and were grown in
RPMI-1640 with 10% fetal calf serum as described [28]. HTB-186
(Daoy) andHTB-85 (SAOS-2) were derived fromATCC and originated
from desmoplastic cerebellar medulloblastoma and primary human
osteosarcoma, respectively.
RNA, DNA, and Protein Extraction
RNA and DNA extraction from tissue samples was carried out
using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the
Table 1. Patient Data.
Diagnosis*
GBM AA DA
WHO grade 4 3 2
No. patients 28 6 12
Male 10 3 8
Female 18 3 4
Median (min-max) age (yr) 64 (8-80) 42 (31-72) 42 (2-68)
Clinical follow-up available 25† 6 11
Median follow-up time (mo) 17 33 61
Favorable outcome 8 4 11
Deceased 17 2 0
Median survival (mo) 17.4 49.9 >50‡
*GBM indicates glioblastoma multiforme; AA, anaplastic astrocytoma; DA, diffuse astrocytoma.
†All diagnosed with primary GBM.
‡Not reached after 50 months.
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manufacturer’s instructions. RNA and DNA contents were determined
by photometric measurement. The purity of the extracted RNA and
DNA was assessed by calculating the ratio of extinctions at 260 nm/
280 nm [29]. Values between 1.7 and 2.2 were tolerated. In addition,
the quality of the RNA was assessed by denaturing agarose gel analysis
with EtBr. The intensity of the bands representing the 28S and 18S
rRNA were determined with FluorImager595 (Molecular Dynamics,
Sunnyvale, CA). The ratio of intensities of the 28S/18S rRNA signal
was calculated. Values between 1.5 and 2.5 were acceptable. Protein
extracts were isolated from 105 to 106 growing cells from cell lines, were
washed with phosphate-buffered saline, and briefly mixed using a
vortex mixer with 200 μl of CHAPS buffer [30]. Alternatively, 50 to
100 mg of thawed tissue samples was immediately mechanically
homogenized on ice with three-time pulses for 5 seconds using Ultra-
TURRAX-T8 dispersing tool S8N-5G (IKA, Staufen, Germany) in
200 μl of CHAPS buffer including 20 U of ribonuclease inhibitor
RNasin (Promega, Madison, WI). Buffer extracts were incubated on
ice for 30 minutes and centrifuged at 12,000g for 20 minutes at 4°C.
One hundred sixty microliters of supernatants was transferred to fresh
tubes, snap frozen on dry ice, and stored at −80°C until further use. The
remaining pellets or intact cells were applied for high-quality DNA
isolation with Maxwell 16 DNA Purification Kit (Promega). Protein
concentrations were determined according to Coomassie Protein Assay
Reagent Product protocol (Pierce, Rockford, IL).
TL Analysis
Relative TL was determined by real-time PCR as described [26,27].
Reactions contained 35 ng of DNA isolated with TRIzol reagent and
SYBRGreenPowerMasterMix(AppliedBiosystems,FosterCity,CA).PCR
was performed on ABI PRISM 7000 Sequence Detection System (Ap-
plied Biosystems) under cycling conditions as described previously [27].
Reactions were set up in triplicates with each 100 nM telomere-specific
(T) primers Tel1b 5′-CGGTTTGTTTGGGTTTGGGTTTGGG-
TTTGGGTTTGGGGT-3′ and Tel2b 5′-GGCTTGCCTTACCC-
TTACCCTTACCCTTACCCTTACCCT-3′ as described [27] or in
duplicates with each 100 nM single-copy 36B4 gene (S) primers
36B4u 5′-CAGCAAGTGGGAAGGTGTAATCC-3′ and 36B4d
5′-CCCATTCTATCATCAACGGGTACAA-3′ [26]. C t values with
a SD greater than 0.5 were repeated. Relative quantities (RQ) of T/S
values were calculated in relation to median levels measured in NT
tissue samples according to Pfaffl’s method [31]. Efficiencies used
for calculating Tel and 36B4 PCRwere determined by standard curves
of template DNA dilution series with 0.83 and 0.94, respectively.
Absolute TL measurement was done by TRF analysis with Telo-
TAGGG-Telomere-Length-Assay (Roche, Basel, Switzerland)
according to the manufacturer’s instructions. In brief, 1 μg of high-
quality DNA was digested with RsaI and HinfI restriction enzymes
and separated by 1% agarose gel electrophoresis. Restriction efficiency
was validated by DNA staining and visualization with FluorImager595
(Molecular Dynamics) before blot analysis on positively charged nylon
membranes. Digoxigenin (DIG)-labeled oligo probes were used for
hybridization to detect telomere sequences by luminescence system
with ChemiSmart 5100 and ChemiCapt software (BioRad, Hercules,
CA). Background corrections on TIFF result files were performed with
ImageJ software (National Institutes of Health, Bethesda, MD). Mean
TRFs were determined in kilobase pairs according to the manufacturer’s
instructions (Roche) based on signal intensities from ImageQuant5.0
software (Molecular Dynamics).
TERRA Expression Quantification
Transcript levels of total, 2p, and 18p TERRA were measured after
complementary DNA (cDNA) synthesis with RevertAid First Strand Kit
(Fermentas, Sankt Leon-Rot, Germany) by real-time PCR on ABI
PRISM 7500 Fast Sequence Detection System with FAST SYBR Green
MasterMix (Applied Biosystems). One microgram of RNA was con-
verted with random hexanucleotide primers into cDNA. Aliquots
corresponding to 40 ng of RNA were analyzed in triplicates by real-time
PCR with 200 nM primers each. Total TERRA levels were amplified
with telomere-specific (T) primers under conditions as described for
relative TL measurement. Primers for specific amplification of chromo-
some 2p and 18p TERRA were designed between telomere ends and
known CpG islands [25]. Primers for 2p TERRA are as follows: chr2_F
5′-TAAGCCGAAGCCTAACTCGTGTC-3′ and chr2_R 5′-
GTAAAGGCGAAGCAGCATTCTCC-3′; those for 18p-TERRA
are as follows: chr18_F 5′-CCTAACCCTCACCCTTCTAAC-3′ and
chr18_R 5′-TACCTCGCTTTGGGACAAC-3′. Amplicons were veri-
fied by sequencing. Relative quantities (RQ) were determined in relation
to levels of 36B4 and to the median expression found in NT tissue sam-
ples according to Pfaff l’s method [31]. Efficiencies of PCRs were deter-
mined and used for quantitative RQ calculation.
Bisulfite Allelic Sequencing
Onemicrogram ofDNAwas subjected to bisulfite conversion by Epitect
reagent (Qiagen, Hilden, Germany). PCR was performed on iCycler
(BioRad) with touchdown PCR protocol as described [25]. Aliquots
corresponding to 20 ng of bisulfite-converted DNA were analyzed
for methylation of CpG islands of chromosome 2p subtelomere region.
Twenty-microliter reactions were set up with primer HC_MP2fwd 3′-
GTATTGTAGGTGTATAGTTGTATAAG-5′ and a modified
primer HC_MP2rev 3′-TAATACGACTCACTATAGGGGATC-
GATCTAAAATTCCACCTATCTCTATAC-5′. HC_MP2rev was
extended at the 5′-end by T7 primer sequence to allow direct sequencing.
PCR fragments of 156 bp in size were purified by 3% agarose (BIOzym,
Hessisch Oldendorf, Germany) gel electrophoresis. The extent of meth-
ylation was determined by direct sequencing of PCR fragments (Qiagen).
In brief, all sequencing reactions were set up with 8 ng of DNA template
and 10 pmol of T7 primer per reaction and cycled with BigDye3.1 Ter-
minator (Applied Biosystems) on GeneAmp PCR System 9700 (Applied
Biosystems) and purified using DyeEx (Qiagen). Data collection was per-
formed on 3730xl DNA Analyzer (Applied Biosystems) equipped with
50-cm capillary arrays and POP7 polymer. Raw data channels from ab1
result files were processed using customized software (Qiagen) for compen-
sation of different dye migration, baseline correction, peak detection, and
base calling. For each base, the area was calculated from the corresponding
peak to measure the base’s quantity. Bases that correspond to variable posi-
tions of CpG sites were identified by comparison with a reference sequence.
Ratios of methylated versus unmethylated CpG sites were reported with
accuracy in the range of ±5% when signal-to-noise ratio was 20 or higher.
Telomerase Activity Analysis
TA was quantified as the total product generated (TPG) units per
0.6 μg of protein extract analyzed by TRAP assay as described
[32,33]. In brief, 0.6 μg of protein extract in CHAPS lysis buffer
was used for each assay in a 20-μl volume setup. Each reaction
contained buffer, dNTPs, 0.8 U of titanium Taq DNA polymerase
(Clontech, Mountain View, CA) and primers for telomerase products
(telomerase substrate [TS] and anchored return CX [ACX] primers)
and for PCR control (telomerase substrate–nontelomerase [TSNT]
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internal control oligonucleotide and nontelomerase [NT] internal
control primer). Reactions were run in duplicates on iCycler (BioRad)
under the following conditions: 30 minutes at 30°C, 1 minute at
95°C, 32× (30 seconds at 94°C, 30 seconds at 59°C, 60 seconds at
72°C). Amplicons were separated on 12% polyacrylamide gels, stained
with VistraGreen (Amersham Biosciences, NJ) and visualized by
FluorImager595 (Molecular Dynamics). Staining intensities of the
telomeric DNA ladder were corrected by signals obtained from controls
with protein lysates heated to 85°C for 10 minutes to inactivate TA.
Furthermore, intensities were normalized with values obtained from
PCR controls. TSR8 oligonucleotide contains sequences for TS primer
and eight telomeric repeat products and was used in separate reactions as
standard for TA quantitation in TPG units. One TPG unit corresponds
to 0.001 amoles (∼600 molecules) of TSR8 extended by at least four
telomeric repeats within 30 minutes at 30°C. Transcript levels for 18S
rRNA were determined with TaqMan chemistry (Applied Biosystems)
on 10-fold dilutions of protein extracts as described [34] to avoid false-
negative results. Samples with levels of 18S rRNA less than 10% of the
mean of all results were scored not determinable for TA.
Statistical Analysis
All statistical tests were two sided, and P ≤ .05 was considered
significant. Statistical analysis was performed with GraphPad Prism
software package (Version 5; GraphPad Software, Inc, San Diego, CA).
Correlations among RQ and activity values were assessed after log trans-
formation with the Pearson correlation calculation.Mann-WhitneyU test
was used for RQ group comparisons. Mean TL in kilobase pairs was
calculated from relative PCR values by linear regression analyses from
a subset of samples analyzed for TRF. Kaplan-Meier analysis and the
log-rank test were used to illustrate differences between overall survivals
to parameters assessed by experiments.
Results
TERRA Expression and Comparison with
Histopathology Grading
Tissue samples from patients with diagnosis for astrocytoma WHO
grade 2 to 4 and NT tissues (Table 1) were analyzed for TERRA
expression. A panel of 14 tumor cell lines, including 12 that originated
from astrocytoma, was also included.
The PCR assay for TL measurement used cDNA instead of
genomic DNA for total TERRA expression analysis. In addition to
this assay, amplifying all expressed telomere repeats, we also estab-
lished subtelomeric region PCR assays to detect chromosome-specific
TERRA from chromosomal ends 2p and 18p. RNA was isolated from
snap-frozen tissue and used for further analyses when it was of ade-
quate quality as described under Materials and Methods. RQs for
TERRA expression were determined in comparison to the expression
of ribosomal gene 36B4 and to the median TERRA expression values
in NT tissues (Figure 1). Similar results were obtained when β-actin
was used instead of 36B4 as a housekeeping control gene. RQ values
for 2p and 18p TERRA normalized on 36B4 correlated strongly with
values normalized on β-actin after log transformation (Pearson r =
0.92, P < .0001; not shown). Total TERRA expression gradually de-
creased in astrocytoma as the grade increased (Figure 1A). In detail,
GBM demonstrates 14-, 31-, and 313-fold decrease compared with
anaplastic astrocytoma (AA), diffuse astrocytoma (DA), and NT tis-
sue, respectively. Although not significant, the expression of TERRA
from chromosome end 2p trended the relation with tumor grade
(Figure 1B). 2p TERRA expression in GBM decreased six-fold com-
pared with NT tissue. In contrast, 18p TERRA expression demon-
strates no relation with tumor grade. Log-transformed RQ values of
total TERRA correlated in vivo with both transformed values of 2p
and 18p TERRA, Pearson r = 0.53 and 0.34, respectively (not shown).
The interesting correlation of 2p TERRA in contrast to the weak
correlation of 18p TERRA may indicate a prevalence of 2p over 18p
TERRA. Furthermore, expression levels of chromosome-specific
TERRA transcripts were measured generally more than 100-fold less com-
pared with levels of total TERRA. For example, NT cases demonstrate
mean C t values of 24.2, 30.7, and 33.1 for total, 2p, and 18p TERRA,
respectively. Calculating the relative amount of TERRA by the expo-
nent of the C t value differences with base 2 results in an estimated 90-
and 480-fold lower expression of 2p and 18p TERRA compared with
total TERRA levels. Summing up, this may indicate the existence of
different regulation mechanisms for chromosome-specific TERRA
expression in astrocytoma.
Total TERRA expression in cell lines derived from astrocytoma
tumors demonstrates RQ values similar to that measured in tumor
tissues. However, in these cell lines, median RQ values of TERRA
from 2p and 18p were lower when compared with their expression
in vivo. From all cell lines analyzed, the osteosarcoma cell line SAOS-2
demonstrated the highest expression of total and 2p but not 18p
TERRA. CpG islands of the promoters for 2p and 18p TERRA of
SAOS-2 cells were determined recently in vitro as having low and high
levels of methylation, respectively [25]. Thus, the observed chromo-
some-specific TERRA expression may reflect the methylation status
of TERRA promoters also in vivo.
Subtelomere Methylation and TERRA Transcription of
Chromosome 2p
The detailed epigenetic state of a CpG island within the subtelomeric
region positioned approximately 1400 bp from the chromosomal 2p
end [25] was determined by bisulfite allelic sequencing in a subset of
grade 2/3 (n = 5) and grade 4 (n = 7) astrocytoma tumor samples
(Figure 2). Sequence strategy, primer, and CpG positions are outlined
(Figure 2A). Ratios of methylated versus unmethylated were obtained
for 12 of 13 CpG positions analyzed, grouped for low and high 2p
TERRA expression and visualized using a heat map. Average percentage
methylation of the CpG island on chromosome 2p revealed dense
cytosine methylation with little interindividual variation across all
analyzed tumor tissues of 87% ± 5% (mean methylation ± SD) with
occasional less methylated CpG positions occurring (not shown). Two
cell lines served as controls. T98G cells contain low 2p TERRA level of
RQ = 0.0218 and exhibit at CpG positions 1 to 9 very dense average
methylation of 96% ± 3%. In contrast to these cells, SAOS-2 cells con-
tain five-fold more 2p TERRA levels of RQ = 0.1134 and, at CpG
positions 7 to 13, demonstrate a low average methylation of 17% ±
12% similar to a recent report [25].
Tumor tissues with low and high 2p TERRA levels selected for
epigenetic analyzes demonstrated 3.6-fold difference between median
transcript levels (Figure 2B). Mean methylation at the 12 CpG posi-
tions of 2p subtelomeric region analyzed for groups with low and
high 2p TERRA expression differ with 89% and 83%, respectively
(P = .0127). No significant difference in the epigenetic state between
analyzed tumors of low and high grade was evident (P = .6506). Dense
methylation of the analyzed CpG island close to the potential 2p
TERRA promoter correlated with low TERRA expression.
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Comparison of TERRA Expression with
Telomerase Activity and TL
TA and TL were correlated with TERRA transcript levels (Figure 3).
TA was detectable by TRAP assays in tumor tissue samples in 14 GBM
and ranged between 2 and 34 TPG units (Figure 3A). TA was not
detectable in tumor tissue samples diagnosed for AA and DA. Of 14
analyzed tumor cell lines, 11 demonstrated TA with values up to
126 TPG units. The cell lines with no detectable TA were identified
as DBTRG/05MG, YT-BO, and SAOS-2—the last one has been rec-
ognized to use ALT in place of TA [25].
TL was determined by quantitative real-time PCR assay as RQ
values of telomere (T)-to-single-copy gene (S) ratios of the analyzed
samples in relation to the median ratios as measured in the samples of
NT tissues (Figure 3B). TL was increased 3.0-, 3.3-, and 2.8-fold in
low-grade DA and AA tumors and cell lines compared with GBM. In
contrast, TL in NT tissues was 0.15-fold the TL in GBM. TRF anal-
yses resulted in a mean TL in kilobase pairs for a set of 12 tumor
samples (Figure W1A). Log-transformed TL values of both methods
correlated with R2 = 0.4271 and P = . 0212, similar to published data
[27]. Linear regression analyses resulted a fitting line of [log]TRF =
0.6595 ± 0.2416x([log]RQ) + 0.3850 ± 0.2176 and allowed to cal-
culate TL from RQ values as mean TRF lengths in kilobase pairs ±
SD (Figure W2). Nontumor tissues exhibit short mean TRF lengths
of 3.1 ± 2.5 kbp, and tumor tissues of astrocytoma grades 2, 3, and 4
exhibit 21.6 ± 14.9, 17.4 ± 4.5, and 8.8 ± 4.0 kbp, respectively, dem-
onstrating that mean TL was increased in low-grade DA and AA
tumors compared with GBM and NT tissue. Mean TRF lengths of
the cell lines demonstrated with 18.4 ± 10.7 kbp comparable values.
Remarkable, cell lines without detectable TA, like DBTRG/05MG,
YT-BO, and SAOS-2, exhibit the longest telomeres of all cell lines
Figure 1. TERRA expression in DA, AA, GBM, and cell lines (CL) compared to NT. The median RQ value for each individual group is
indicated with horizontal line and is set as 1 for NT. Open circles indicate glioma cell lines; black triangle, Daoy cells; black cross, SAOS-2
cells. (A) Total TERRA shows down-regulation following tumor grades and cell lines. (B) 2p TERRA shows down-regulation for AA and
GBM, and cell lines. (C) 18p TERRA shows no correlation with tumor grade. Results of statistics are indicated as extremely significant
(***P < .001), very significant (**P = .001 to .01), significant (*P = .01 to .05), and not significant (ns, P > .05).
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analyzed. TRF analyses of YT-BO cells demonstrate the same TL pro-
file as is seen in SAOS-2 (Figure W1B). These long telomeres suggest
that the YT-BO astrocytoma cell line may use ALT as TMM [9].
The tumors were grouped according their TMM status (TA positive
or negative, ALT based on high or low TL) and compared with TERRA
expression (Figure 3C ). Moreover, 17% (8/46) of tumors use TA as
TMM, 37% (17/46) use ALT, 13% (6/46) use both TA and ALT,
and for 33% (15/46), no TMM could be identified. Tumors with
TA demonstrate 1.3-, 6-, and 12-fold decrease in total TERRA expres-
sion compared to tumors using both TA and ALT, no TMM, and ALT,
respectively. Thus, total TERRA expression depends on the TMM used
in astrocytomas and is highest if TA is absent. Furthermore, TA levels
and RQ values of total TERRA demonstrate a moderate negative cor-
relation after log transformation (Pearson r = −0.54) in the GBM cases
with detectable TA (Figure 3D).
TMM, TERRA Expression, and Patient Survival
Formost of the patients, overall survival data were available (Table 1).
Median overall survival time correlated with tumor grade. Astrocytoma
grades 4, 3, and 2 demonstrated median survival times of 17.4, 49.9,
and longer than 50 months, respectively.
Figure 2. Subtelomere methylation and expression of chromosome 2p. (A) Upper panel illustrates the localization and sequence of
chromosome 2p subtelomeric region studied. Locations of primers chr2_F and chr2_R used for quantification of 2p TERRA levels by
real-time reverse transcription–polymerase chain reaction are indicated. Sequence represents the amplicon from 2p used for bisulfite
allelic sequencing of 13 CpG positions labeled in red and flanked from both sides by indicated primers. Numbers in brackets indicate
primer positions relative to the telomere. Lower panel shows the mean methylation of individual CpG positions in a panel of astrocytoma
tissue samples and cell lines grouped for high and low expression of 2p TERRA. Colors of circles indicate the percentage of methylation
as defined by heat map. (B) Upper panel shows significant difference of median RQ values (horizontal line) in the samples grouped for
low and high expressions of 2p TERRA (Mann-Whitney test, P = .0025). Lower panels illustrate the difference in mean methylation
(horizontal line) over all tested 13 CpG positions compared to 2p TERRA expression (left) and to tumor type (right) analyzed by unpaired
t test with Welch correction.
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Kaplan-Meier analyses were performed including individuals with all
tumor grades of the study and with GBM only. No differences between
groups defined by TA, TL, and TERRA expression were observed
(Figure W3). However, TA, TL, and total TERRA showed a non-
significant association with patient outcome when all tumor grades
were included. Mantel-Cox test of these analyses revealed P < .1. In
detail, absence of TA, long TL, and low TERRA expression were asso-
ciated with better prognosis (P = .0969, P = .0548, and P = .0563,
respectively). Survival analyses were performed between four TMM
groups defined in Figure 3C , and a significant trend related to defined
combinations between TA and TL was observed with P = .0194
(Figure 4A). Detection of TA and short telomeres predicted worse
prognosis with a median survival time of 14.8 months. In contrast,
the absence of telomerase and long telomeres, indicating ALT, pre-
dicted patients with long (>66 months) overall survival time. Both
groups differ significantly in prediction of survival (P = .0041). Similar
analyses on four groups defined by total TERRA expression levels and TA
status resulted in the observation of a significant trend between groups
with P = .0148 (Figure 4B). Detection of TA and low TERRA levels
predicted worse prognosis with a median survival time of 15.6 months.
In contrast, detection of TA and high TERRA levels predicted best out-
come. The survival difference between the group of individuals with
tumors showing TA and low TERRA levels and the group showing
TA and high TERRA levels analyzed by Mantel-Cox test did not
reach significance (P = .09). However, the survival difference between
the group of individuals with grade 2 to 4 tumors showing TA and low
TERRA and all other individuals was observed (P = .0144). We repeated
all analyses with the GBM data set (Figure 4, C and D). Analyzing four
groups defined by TL levels and TA did not demonstrate any significant
correlations with P value of 0.0934 (Figure 4C). In contrast, analyzing
four groups of GBM defined by TERRA levels and TA resulted in
a significant trend for survival between these groups, with P = .0222
(Figure 4D). Our findings indicate that TERRA expression together
with TA in astrocytoma may be prognostic for survival.
Discussion
In this study, we show that TERRA expression reflects telomerase-
dependent and -independent TMM operating in astrocytoma and
is associated with a favorable outcome. Patients with GBM still
have a dismal prognosis despite aggressive treatment strategies
[14], and new markers that show clinical significance are urgently
needed [35].
Total TERRA expression inversely correlates with tumor grade as
measured by telomeric repeat-specific PCR assay originally developed for
determination of relative TL [26,27]. In comparison to TERRA levels
from chromosome ends 2p and 18p measured by gene-specific PCR
assays, significant more than 100-fold less amounts were detected.
This is supported by the finding that the bulk of telomeric repeats in
TERRA transcripts has an average length of 200 bases [36] and that
beside chromosomes 2p and 18p further chromosome ends are tran-
scribed [23,24]. The TERRA transcript levels from the two analyzed
chromosomes 2p and 18p differ in correlation with tumor grade and
thus indicate that chromosome ends are transcribed and regulated
individually in astrocytoma. Our finding of a diagnostic value of
TERRA levels in astrocytomaWHO grade 2 to 4 correspond with pre-
liminary data in advanced stages of human tumors of larynx, colon, and
lymph node [22].
Further, we show that, in astrocytoma, TERRA expression from
chromosome 2p correlates with cytosine methylation of CpG islands
in the promoter, suggesting epigenetic difference as a mechanism in-
volved in regulation in tumors. These in vivo results were supported
by our finding of pronounced epigenetic differences at TERRA pro-
moter from chromosome 2p between two analyzed cell lines, T98G
and SAOS-2, expressing low and high TERRA levels, respectively,
and which are known to use TA and ALT, respectively. Similar
epigenetic differences were observed in vitro between telomerase-
positive and ALT human cell lines [25,37] and highlight that the
epigenetic state of the telomere may influence TMM as shown in
mice [38].
We evaluated the TMM by analyzing TA and TL as a marker for
ALT in clinical material and cell lines as reported [19]. Fifty percent of
GBM demonstrated TA-positive tumors and TA was undetectable in
all tested astrocytoma grades 2 and 3, as has been reported by others
[15–18]. In contrast, longer telomeres, a feature of tumor cells using
ALT, were found in some of the other GBM samples studied and con-
sistently in grade 2 and 3 tumors of our series. These latter results are
in line with reports that detected ALT in 88% (7/8) of astrocytoma
grades 2 and 3 and in 24% (26/109) or 15% (86/573) of GBM [8,20].
A recent report supports the finding of almost exclusive ALT-positive
tumors in astrocytoma grades 1 to 3 with 93% [39]. Wemainly studied
cell lines derived from high-grade tumors, and most demonstrated TA.
In contrast, two studied cell lines revealed no detectable TA, but long
Figure 2. (continued).
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telomeres were recognized and thus may represent candidates for ALT
cell models [9]. Supporting our in vitro findings, a cell line was estab-
lished recently from GBM, which demonstrated the ALT phenotype
and furthermore showed characteristics of glioma stem cells [40]. Thus,
in vitro both TA and ALT were shown to maintain the telomeres of
GBM and were associated with treatment-resistant glioma stem cells.
These cell lines are currently analyzed for TMM and tumor stem cell
properties at our laboratory. Tumors grouped according their TL and
TA status correlated with TERRA expression. TERRA expression was
high in tumors with long telomeres and absent TA and low in tumors
with short telomeres and detectable TA, suggesting that TERRA is
associated with TA and ALT as TMM in astrocytoma. This finding
together with the resulting inverse linear correlation between TA units
and TERRA expression suggests an inhibitory function of TERRA on
TA in astrocytoma. Indeed, TERRA was recognized in vitro as a natural
ligand and direct inhibitor of telomerase [41]. Direct inhibition of
telomerase enzymatic activity has shown efficiency against glioma cell
lines and xenografts [42–44], and first telomerase-based cancer therapy
approaches are tested in clinical studies [45]. Thus, TERRA could be
a further candidate for clinical prognosis, like O-methylguanine
methyltransferase promoter methylation for alkylating agent in chemo-
therapy [35].
TMM status did correlate with overall survival of all tumors stud-
ied. TA was identified exclusively in a subset of GBM and together
with short telomeres resulted in the worst median survival time of
14.8 months. In contrast, total TERRA levels correlated with
TMM, in detail with low or absent TA and presence of long telo-
meres indicating ALT and were associated with a favorable patient
Figure 3. TA and TL compared to TERRA expression in astrocytoma. (A) TA was detectable in GBM and most of cell lines studied.
Horizontal line represents the median and in groups DA and AA indicate the detection limit. (B) The median RQ value for relative TL
of each individual group is indicated with a horizontal line and is set as 1 for NT. (C) TERRA expression and TMM. Tumors from patients
were grouped: TA detected (TA pos), TA undetected (TA neg), long telomeres (TL high) indicating ALT, and short telomeres (TL low)
indicating absence of ALT. Median TL of all tumors studied defined groups for long and short telomeres. The median RQ value for total
TERRA expression of each individual group is indicated with a horizontal line. (D) Linear regression analyses of TA TPG units and total
TERRA RQ values show a negative relation. Slashed lines indicate 95% confidence interval; black line, linear regression line best fitting
the data.
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prognosis. High TA and expression were reported to be significant
predictors of worse prognosis in astrocytoma of higher grades [17].
In contrast, long telomeres and ALT have been associated with better
outcome in grade 4 tumors [19,20] and are detected more common
in astrocytoma of lower grades [8]. Survival of patients with GBM
grouped for TA, TL, and TERRA expression did not result in a cor-
relation with outcome. However, analyzing combined groups defined
by TERRA and TA did result in a trend for survival between these
groups, for both patients with astrocytoma including all grades and
with GBM. In detail, detection of TA and low TERRA levels pre-
dicted worse prognosis with a median survival time of 15.6 months.
In contrast, detection of TA and high TERRA levels predicted best
outcome. Our data suggest that TERRA expression together with TA
in astrocytoma might be of prognostic significance. Future studies
including higher numbers of GBM may allow the identification of
an association between survival and TERRA expression within sub-
types of GBM, similar to those published for GBM subtypes using
ALT as TMM with clear survival benefit [19,20], and for GBM sub-
types identified based on gene signatures with differences in methyl-
ation phenotype and therapy response [46].
In summary, our data indicate that total TERRA levels are down-
regulated in astrocytoma involving epigenetic silencing by promoter
methylation and reflect TMM status with prognostic potential. Fur-
thermore, we show that TERRA originating from different chromo-
some ends is independently regulated. It remains to be investigated
how individual TERRA transcripts may influence the TMM of all or
single chromosomes. Our results of TERRA expression and TA
showed correlation with outcome in this patient series, suggesting
that further investigation into the correlation of TERRA and TA
as prognostic markers in gliomas is worthwhile. Further, our findings
suggest the importance of analyzing TERRA and TA especially in
clinical trials with telomerase as a treatment target investigating re-
sponsiveness and resistance.
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Figure W1. Mean TL analyses by TRF Southern blots. (A) TRF blots of a set of tumor tissue samples. (B) TRF blots of cell lines. Lanes
with molecular weight size markers (Ma) and standards from Telo-TAGGG-Telomere-Length-Assay with long (St high) and short (St low)
telomeres applied with different amounts are indicated. DNA stained with EtBr was visualized in agarose gels before blot analysis and
shown below each TRF blot. GBM11 was applied without restriction digest (GBM11 uncut) to validate the system. Results obtained with
applied different amounts of telomere standard (St high; 40, 200, and 760 ng) indicate the broad reproducibility of the method. For
further validation, DNA extracted from SAOS-2 by TRIzol reagent was applied in lane SAOS-2* and resulted in a different telomere
pattern when compared to DNA extracted by high-quality DNA isolation system (lane SAOS-2). Thus, only high-quality DNA isolation
was applied for TRF analyses. Mean TRFs in kilobase pairs were determined, and they are indicated as white bars.
Figure W1. (continued).
Figure W2. Linear regression analyses of TRF and quantitative
PCR results. Relative T/S-RQ values determined by quantitative
PCR and mean TRF lengths in kilobase pairs determined by South-
ern blots correlated after log transformation. The resulting equation
for the linear regression line best fitting the data, the correlation
coefficient, and the P value are shown. The table sums up the mean
TRF values in kilobase pairs and SD for individual groups after
conversion of the relative T/S-RQ values with the equation.
Figure W3. Kaplan-Meier analysis for overall survival defined as time from diagnosis until astrocytoma-related death. Individuals were
pooled into two groups and analyzed for association with survival using patients with astrocytoma of all grades studied (left) or GBM
(right). P values indicate significance of survival differences between the groups. (A) For TA, patients were grouped in positive or negative,
when TA was detectable or absence, respectively. For TL, patients were pooled in groups of long and short telomeres, in TL high and
TL low, respectively. (B) For total, 2p, and 18p TERRA, patients were pooled in groups of high and low expression.
Figure W3. (continued).
